Skip to main content

Table 1 Patient characteristics

From: Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer

 

All

Synchronous

Metachronous

p

Total no. of patients

75

39

36

 

Age, years

    

 mean ± SD

59.1 ± 8,4

59.5 ± 9,1

58.5 ± 7,6

0.63b

 range

39-77

39-77

42-77

 

Sex, no. (%)

    

 Male

43 (57)

23 (59)

20 (56)

0.76c

 Female

32 (43)

16 (41)

16 (44)

 

KPS, no. (%)

    

 70

9 (12)

3 (8)

6 (17)

 

 80

38 (51)

14 (36)

24 (66)

0.002d

 90

28 (37)

22 (56)

6 (17)

 

Weight loss, no. (%)

    

 <5%

65 (87)

36 (92)

29 (81)

0.18e

 >5%

10 (13)

3 (8)

7 (19)

 

Histology

    

 Adenocarcinoma

50 (67)

26 (67)

24 (66)

 

 Squamous

17 (23)

9 (23)

8 (22)

1.0d

 Other

8 (10)

4 (10)

4 (11)

 

T-Stagea, no. (%)

    

 T1

11 (15)

3 (8)

8 (22)

 

 T2

37 (50)

21 (54)

17 (47)

0.36c

 T3

12 (16)

7 (18)

5 (14)

 T4

14 (19)

8 (20)

6 (17)

 

N-Stagea, no. (%)

    

 N0

28 (38)

10 (25)

19 (53)

 

 N1

14 (19)

7 (18)

7 (19)

0.06d

 N2

28 (38)

19 (49)

9 (25)

 

 N3

4 (5)

3 (8)

1 (3)

 

Thoracic UICC stage, no. (%)

    

 IA

4 (5)

1 (3)

3 (8)

 

 IB

7 (9)

4 (10)

3 (8)

 

 IIA

14 (19)

6 (15)

9 (25)

0.08d

 IIB

10 (14)

2 (5)

8 (22)

 IIIA

25 (34)

17 (44)

8 (22)

 

 IIIB

14 (19)

9 (23)

5 (14)

 

Localization of metastases, no. (%)

    

 Brain

51 (62)

26 (59)

25 (65)

 

 Bone

7 (8)

5 (11)

2 (5)

 

 Lung

9 (11)

5 (11)

4 (11)

 

 Lymphatic

5 (6)

4 (9)

1 (3)

0.16d

 Adrenal Gland

3 (4)

3 (7)

0

 

 Soft tissue

3 (4)

0

3 (8)

 

 Other

4 (5)

1 (2)

3 (8)

 

No. of metastases, no. (%)

    

 1

57 (76)

29 (74)

28 (78)

 

 2

11 (15)

6 (15)

5 (14)

1.0d

 3–5

7 (10)

4 (10)

3 (8)

 

No. of involved organs, no. (%)

    

 1

68 (91)

34 (87)

34 (95)

0.43e

 > 2

7 (9)

5 (13)

2 (5)

 

Treatment of primary tumor, no. (%)

    

 Surgery ± (neo)adjuvant RT and/or CT

55 (73)

26 (66)

29 (80)

 

 RCT

18 (24)

12 (31)

6 (17)

0.34d

 SBRT

2 (3)

1 (3)

1 (3)

 

Treatment of oligometastases, no. (%)

    

 Surgery

12 (14)

7 (16)

5 (13)

 

 SRS/hSRT/SBRT

19 (23)

10 (22)

9 (23)

0.88d

 Surgery/RT combined

49 (58)

25 (56)

24 (61)

 cf-RT

4 (5)

3 (7)

1 (3)

 

FDG-PET based staging, no. (%)

51 (68)

34 (87)

17 (47)

 

Additional chemotherapy, no. (%)

48 (64)

27 (69)

21 (58)

 

FEV1, % predicted

    

 mean ± SD

76 ± 24

77 ± 27

74 ± 20

0.20b

  1. SD standard deviation, RT radiotherapy, CT chemotherapy, RCT radiochemotherapy, SBRT stereotactic body radiotherapy, SRS stereotactic radiosurgery, hSRT hypofractionated stereotactic radiosurgery, cf-RT conventionally fractionated radiotherapy, KPS Karnofsky Performance Score, FEV1 Forced expiratory volume during 1st second of breathing maneuver
  2. arefers to initial staging also for patients with metachronous metastases
  3. bf-test for unpaired samples was used
  4. cchi-square test was used
  5. dFisher-Freeman-Halton test was used
  6. eFisher's exact test was used